Cargando…

Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response

Both innate and adaptive immunity underpin cancer immunosurveillance. To stimulate both these arms of the immune system, we used allogeneic cells loaded with natural killer T (NKT) cell ligands and expressing tumor-associated antigens, resulting in NKT cell activation, dendritic-cell maturation and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Shin-ichiro, Shimizu, Kanako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654573/
https://www.ncbi.nlm.nih.gov/pubmed/23734303
http://dx.doi.org/10.4161/onci.23432
_version_ 1782269582540537856
author Fujii, Shin-ichiro
Shimizu, Kanako
author_facet Fujii, Shin-ichiro
Shimizu, Kanako
author_sort Fujii, Shin-ichiro
collection PubMed
description Both innate and adaptive immunity underpin cancer immunosurveillance. To stimulate both these arms of the immune system, we used allogeneic cells loaded with natural killer T (NKT) cell ligands and expressing tumor-associated antigens, resulting in NKT cell activation, dendritic-cell maturation and ultimately in the elicitation of adaptive T-cell responses. This approach holds great promise for the development of novel anticancer immunotherapies.
format Online
Article
Text
id pubmed-3654573
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545732013-06-03 Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response Fujii, Shin-ichiro Shimizu, Kanako Oncoimmunology Author's View Both innate and adaptive immunity underpin cancer immunosurveillance. To stimulate both these arms of the immune system, we used allogeneic cells loaded with natural killer T (NKT) cell ligands and expressing tumor-associated antigens, resulting in NKT cell activation, dendritic-cell maturation and ultimately in the elicitation of adaptive T-cell responses. This approach holds great promise for the development of novel anticancer immunotherapies. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654573/ /pubmed/23734303 http://dx.doi.org/10.4161/onci.23432 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Fujii, Shin-ichiro
Shimizu, Kanako
Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
title Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
title_full Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
title_fullStr Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
title_full_unstemmed Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
title_short Immunotherapy with artificial adjuvant vector cells: Harnessing both arms of the immune response
title_sort immunotherapy with artificial adjuvant vector cells: harnessing both arms of the immune response
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654573/
https://www.ncbi.nlm.nih.gov/pubmed/23734303
http://dx.doi.org/10.4161/onci.23432
work_keys_str_mv AT fujiishinichiro immunotherapywithartificialadjuvantvectorcellsharnessingbotharmsoftheimmuneresponse
AT shimizukanako immunotherapywithartificialadjuvantvectorcellsharnessingbotharmsoftheimmuneresponse